Non-Small Cell Lung Cancer

Featured

Guideline Updates
NCCN Updates Clinical Practice Guideline for NSCLC
The NCCN released an update to include cemiplimab-rwlc as a preferred, category 1, treatment option for PD-L1 expression-positive NSCLC ≥50%.
News
Nivolumab Effective for Advanced NSCLC in Real-World Practice
Study results show nivolumab monotherapy is effective for previously treated advanced NSCLC in real-world practice.
News
Higher Out-of-Pocket Costs Associated With Decreased TKI Adherence in NSCLC
Higher out-of-pocket costs for TKIs are associated with decreased therapy adherence among patients with EGFR- and ALK-…
Quiz
Quiz: Impact of Out-of-Pocket Costs in NSCLC
True or False: Higher out-of-pocket costs for TKIs among patients with EGFR- and ALK-positive advanced NSCLC are…
News
Anticancer Therapy Small Driver of Unplanned Hospital Care for Patients With NSCLC
Study findings show TKI therapy, immunotherapy, and chemotherapy are relatively small drivers of unplanned acute…

News

Higher Out-of-Pocket Costs Associated With Decreased TKI Adherence in NSCLC
Anticancer Therapy Small Driver of Unplanned Hospital Care for Patients With NSCLC
Timely Specialty Palliative Care for NSCLC Associated With Cost-Savings
NGS Panel Using ctDNA Accurately Identifies Key Driver Alterations in Advanced NSCLC

Guideline Updates

NCCN Updates Clinical Practice Guideline for NSCLC

Interviews

Assessing a New Potential Standard of Care in First-Line Metastatic, Non-Squamous NSCLC

Videos

Exploring the New IVI NSCLC Value Modeling Platform

Podcast

Episode 28: Advances in NSCLC With Nathan Pennell

Conference Coverage

Nivolumab Plus Ipilimumab Associated With Lower Costs Than Other First-Line Regimens for NSCLC
Back to Top